



MEN

FIRST CANCER SITE
LIVERLIVER
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

FEGATO
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months		
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR		
SECOND CANCER SITE			O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR		
ALL SITES, BUT SKIN AND LIVER	662	38090	662	0.86	934	1.08	272	2.84	199	0.73	371	0.91	80	1.06	12	0.75	-2.79	1.63
HEAD AND NECK	71	38090	71	2.19	84	2.29	13	3.08	19	1.60	46	2.70	6	2.03	0	0.00	1.01	1.10
ORAL CAVITY	21	38090	21	2.79	24	2.83	3	3.10	7	2.57	14	3.54	0	0.00	0	0.00	0.35	0.36
PHARYNX	20	38090	20	2.92	20	2.59	0	0.00	5	2.00	12	3.32	3	4.75	0	0.00	0.35	0.29
LARYNX	30	38090	30	1.66	40	1.96	10	4.21	7	1.05	20	2.11	3	1.85	0	0.00	0.31	0.46
OESOPHAGUS	17	38090	17	2.08	30	3.25	13	12.21	3	1.02	14	3.26	0	0.00	0	0.00	0.23	0.48
STOMACH	37	38090	37	0.84	46	0.92	9	1.51	7	0.44	26	1.14	3	0.72	1	1.09	-0.18	-0.09
COLON RECTUM	83	38090	83	0.77	103	0.85	20	1.50	28	0.74	44	0.77	10	0.93	1	0.43	-0.66	-0.44
COLON	54	38090	54	0.73	71	0.85	17	1.86	17	0.66	29	0.74	7	0.94	1	0.61	-0.54	-0.29
RECTUM	29	38090	29	0.86	32	0.84	3	0.71	11	0.92	15	0.84	3	0.90	0	0.00	-0.13	-0.14
LIVER	2	38090	2	0.06	2	0.05	0	0.00	1	0.08	1	0.06	0	0.00	0	0.00	-0.84	-0.85
GALLBLADDER	4	38090	4	0.47	5	0.52	1	0.92	1	0.33	2	0.44	1	1.21	0	0.00	-0.12	-0.11
PANCREAS	9	38090	9	0.42	13	0.54	4	1.50	1	0.13	6	0.53	1	0.47	1	2.18	-0.32	-0.26
LUNG	117	38090	117	0.83	182	1.15	65	3.60	40	0.79	63	0.85	13	0.98	1	0.36	-0.62	0.54
SKIN MELANOMA	8	38090	8	0.73	11	0.90	3	2.35	1	0.27	4	0.68	3	2.62	0	0.00	-0.08	-0.03
MESOTHELIOMA	1	38090	1	0.23	5	1.03	4	7.80	1	0.67	0	0.00	0	0.00	0	0.00	-0.09	0.00
KAPOSI SARCOMA	4	38090	4	2.34	4	2.07	0	0.00	1	1.62	3	3.33	0	0.00	0	0.00	0.06	0.05
SOFT TISSUE	6	38090	6	2.25	7	2.33	1	3.03	3	3.20	1	0.71	2	7.56	0	0.00	0.09	0.09
BONE	0	38090	0	0.00	1	1.28	1	11.08	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	0.01
BREAST	1	38090	1	0.59	1	0.52	0	0.00	0	0.00	0	0.00	1	5.99	0	0.00	-0.02	-0.02
PROSTATE	110	38090	110	0.68	162	0.89	52	2.73	33	0.60	63	0.73	12	0.72	2	0.56	-1.37	-0.45
TESTIS	1	38090	1	1.38	1	1.22	0	0.00	0	0.00	0	0.00	0	0.00	1	51.32	0.01	0.00
KIDNEY AND RENAL PELVIS	18	38090	18	0.73	29	1.05	11	3.68	4	0.47	7	0.54	6	2.45	1	1.93	-0.17	0.03
BLADDER AND URINARY TRACT	81	38090	81	0.90	117	1.15	36	3.18	29	0.90	43	0.90	8	0.92	1	0.55	-0.24	0.36
URINARY BLADDER	78	38090	78	0.90	112	1.15	34	3.13	29	0.94	40	0.88	8	0.96	1	0.57	-0.22	0.34
URINARY TRACT	3	38090	3	0.82	5	1.22	2	4.25	0	0.00	3	1.57	0	0.00	0	0.00	-0.02	0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	2	38090	2	0.22	2	0.19	0	0.00	0	0.00	1	0.20	1	1.13	0	0.00	-0.19	-0.20
THYROID	3	38090	3	0.82	8	1.95	5	11.89	1	0.79	1	0.51	1	2.65	0	0.00	-0.02	0.09
HODGKIN LYMPHOMA	0	38090	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	30	38090	30	1.34	35	1.39	5	1.81	7	0.89	18	1.52	5	2.28	0	0.00	0.20	0.23
MYELOMA	11	38090	11	1.07	13	1.13	2	1.53	6	1.65	4	0.74	0	0.00	1	4.62	0.02	0.03
LEUKAEMIAS	13	38090	13	0.73	22	1.10	9	3.91	6	0.94	6	0.64	0	0.00	1	2.79	-0.12	0.05
LYMPHOID LEUKAEMIAS	9	38090	9	1.05	15	1.55	6	5.38	4	1.29	4	0.89	0	0.00	1	6.04	0.01	0.12
MYELOID LEUKAEMIAS	4	38090	4	0.50	6	0.66	2	1.96	2	0.70	2	0.48	0	0.00	0	0.00	-0.11	-0.07
OTHER LEUKAEMIAS	0	38090	0	0.00	1	0.75	1	6.05	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.01
OTHER AND ILL DEFINED SITES	35	38090	35	0.87	53	1.17	18	3.51	8	0.56	19	0.90	7	1.79	1	1.16	-0.13	0.18

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
LIVERLIVER
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

FEGATO
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	10720		15712		15712		10720		5018		751		140		10720	15712
Person-years ▶	16417		18587		2169		5879		8354		1759		425		16417	18587
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND LIVER	160	0.81	216	0.97	56	2.10	55	0.78	76	0.76	24	1.13	5	0.93	-2.26	-0.42
HEAD AND NECK	8	3.19	8	2.81	0	0.00	1	1.12	5	3.91	1	3.68	1	14.89	0.33	0.28
ORAL CAVITY	3	2.16	3	1.91	0	0.00	1	2.04	1	1.42	0	0.00	1	26.14	0.10	0.08
PHARYNX	3	5.91	3	5.22	0	0.00	0	0.00	3	11.57	0	0.00	0	0.00	0.15	0.13
LARYNX	2	3.25	2	2.87	0	0.00	0	0.00	1	3.18	1	15.25	0	0.00	0.08	0.07
OESOPHAGUS	3	3.03	4	3.54	1	7.10	0	0.00	2	4.01	1	9.32	0	0.00	0.12	0.15
STOMACH	11	0.94	13	0.96	2	1.11	5	1.16	5	0.86	1	0.80	0	0.00	-0.05	-0.03
COLON RECTUM	16	0.49	26	0.71	10	2.24	7	0.61	4	0.24	4	1.14	1	1.09	-1.00	-0.59
COLON	12	0.51	21	0.79	9	2.80	4	0.48	4	0.34	3	1.17	1	1.50	-0.69	-0.30
RECTUM	4	0.44	5	0.49	1	0.80	3	0.92	0	0.00	1	1.04	0	0.00	-0.31	-0.28
LIVER	0	0.00	1	0.14	1	1.15	0	0.00	0	0.00	0	0.00	0	0.00	-0.39	-0.34
GALLBLADDER	1	0.21	2	0.37	1	1.46	0	0.00	0	0.00	1	2.04	0	0.00	-0.23	-0.18
PANCREAS	5	0.58	5	0.51	0	0.00	1	0.33	3	0.68	1	1.04	0	0.00	-0.22	-0.26
LUNG	11	0.83	16	1.06	5	2.90	1	0.22	7	1.03	2	1.35	1	2.66	-0.14	0.05
SKIN MELANOMA	3	0.90	4	1.06	1	2.35	0	0.00	2	1.17	0	0.00	1	10.34	-0.02	0.01
MESOTHELIOMA	1	1.76	2	3.14	1	14.21	1	5.12	0	0.00	0	0.00	0	0.00	0.03	0.07
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
SOFT TISSUE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.05
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	37	0.77	52	0.96	15	2.39	14	0.82	19	0.77	4	0.77	0	0.00	-0.67	-0.12
CERVIX UTERI	6	2.52	6	2.21	0	0.00	2	2.27	3	2.49	1	4.15	0	0.00	0.22	0.18
CORPUS UTERI	5	0.54	8	0.77	3	2.51	2	0.61	1	0.21	1	1.04	1	4.43	-0.25	-0.13
OVARY	3	0.49	3	0.43	0	0.00	1	0.45	1	0.32	1	1.54	0	0.00	-0.19	-0.21
KIDNEY AND RENAL PELVIS	3	0.60	4	0.71	1	1.55	2	1.15	1	0.39	0	0.00	0	0.00	-0.12	-0.09
BLADDER AND URINARY TRACT	10	1.24	16	1.75	6	5.44	4	1.40	6	1.47	0	0.00	0	0.00	0.12	0.37
URINARY BLADDER	10	1.33	16	1.88	6	5.84	4	1.50	6	1.58	0	0.00	0	0.00	0.15	0.40
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	2	0.65	2	0.58	0	0.00	0	0.00	1	0.64	1	3.05	0	0.00	-0.06	-0.08
THYROID	5	1.61	6	1.73	1	2.72	1	0.93	2	1.25	2	5.81	0	0.00	0.12	0.14
HODGKIN LYMPHOMA	1	2.33	1	2.05	0	0.00	0	0.00	1	4.59	0	0.00	0	0.00	0.03	0.03
NON-HODGKIN LYMPHOMA	6	0.77	8	0.90	2	1.94	3	1.09	2	0.50	1	1.18	0	0.00	-0.11	-0.05
MYELOMA	6	1.60	6	1.41	0	0.00	2	1.49	2	1.05	2	4.96	0	0.00	0.14	0.09
LEUKAEMIAS	5	0.96	5	0.84	0	0.00	3	1.59	2	0.76	0	0.00	0	0.00	-0.01	-0.05
LYMPHOID LEUKAEMIAS	3	1.30	3	1.13	0	0.00	3	3.52	0	0.00	0	0.00	0	0.00	0.04	0.02
MYELOID LEUKAEMIAS	2	0.82	2	0.72	0	0.00	0	0.00	2	1.62	0	0.00	0	0.00	-0.03	-0.04
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
OTHER AND ILL DEFINED SITES	12	0.78	19	1.09	7	3.19	5	0.91	7	0.91	0	0.00	0	0.00	-0.20	0.08

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio